Panminerva medica
-
Multicenter Study
Clinical use of cangrelor: a real world multicenter experience from South Italy Insights from the M.O.Ca. registry.
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and oral P2Y
12 inhibitor (P2Y12 -I) represents the standard of care for patients with acute coronary syndromes (ACS) or with chronic coronary syndromes (CCS) treated with percutaneous coronary intervention (PCI). Cangrelor, the first intravenous P2Y12 -I, is deemed to overcome the drawbacks of the oral administration; nevertheless, real world data on this new drug are scanty. We sought to investigate routine clinical use of cangrelor in four interventional centers of Italy. ⋯ Cangrelor was predominantly used in ACS with modalities substantially in accord with the label indications. Poor clinical outcomes are due to the prevalent utilization in highly challenging clinical settings, nevertheless the rate of bleeding and stent thrombosis are in line with the randomized trials if analyzed in a subpopulation of comparable risk profile.